This conceptual MoA animation is the teaser edit of a video about a new multi-modal antidepressant therapy.
Recognizing the benefits of conventional antidepressants and also the unmet needs of patients, scientists at Lundbeck set out to create a new molecule for the treatment of depression.
Their approach was to combine an SSRI with5-HT1A receptor agonism; this would block both the serotonin reuptake transporter and modulate 5-HT1A receptors to produce a rapid onset of action and an augmentation of the serotonin response. They had discovered Vortioxetine – a multimodal molecule.
But the profile of vortioxetine doesn’t end with direct effects on the serotonin transporter and several 5-HT receptors; in vivo studies also show that the molecule leads to the elevation of multiple neurotransmitters, including serotonin, noradrenaline, dopamine, acetylcholine, glutamate,and histamine, and to a reduction in GABA.